NasdaqGS:CGONBiotechs
How Investors May Respond To CG Oncology (CGON) Expanding ATM Offering To Advance Cretostimogene BLA Efforts
In recent days, CG Oncology drew attention as multiple research firms updated their views on the company, while it expanded its at-the-market stock offering to up to US$550 million to support progress toward a Biologics License Application for its bladder cancer therapy candidate, cretostimogene.
Analysts pointed to recent clinical and market validation in intermediate-risk non-muscle invasive bladder cancer and CG Oncology’s advancing PIVOT-006 trial as important factors shaping how...